Page last updated: 2024-12-05

2-methylbenzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Methylbenzimidazole is a heterocyclic organic compound with the formula C8H8N2. It is a white solid that is soluble in water and organic solvents. 2-Methylbenzimidazole has been studied for its potential medicinal properties, particularly its ability to inhibit the growth of certain types of cancer cells. The compound has also been investigated for its potential use as a pesticide and a fungicide. The synthesis of 2-methylbenzimidazole is typically achieved through a condensation reaction between o-phenylenediamine and acetic anhydride. The compound's effects are diverse, including anti-cancer activity, anti-inflammatory activity, and anti-microbial activity. 2-Methylbenzimidazole is studied for its potential medicinal applications, its environmental effects, and its ability to interact with other molecules.'

Cross-References

ID SourceID
PubMed CID11984
CHEMBL ID309135
CHEBI ID194887
SCHEMBL ID111276
MeSH IDM0285018

Synonyms (67)

Synonym
5-23-06-00320 (beilstein handbook reference)
unii-zh8iww7y8b
30304-58-6
zh8iww7y8b ,
1h-benzimidazole, methyl-
BB 0240414
wln: t56 bm dnj c1
615-15-6
acetamidine, n-n'-o-phenylene-
methyl-2-benzimidazole
nsc-6500
2-methylbenzimidazole
benzimidazole, 2-methyl-
1h-benzimidazole, 2-methyl-
nsc6500
AE-641/30396016
2-methyl-1h-benzimidazole
brn 0112264
einecs 210-411-9
ai3-51528
nsc 6500
2-methyl-1h-benzo[d]imidazole
inchi=1/c8h8n2/c1-6-9-7-4-2-3-5-8(7)10-6/h2-5h,1h3,(h,9,10
2-methylbenzimidazole, 98%
STK057579
CHEMBL309135 ,
2-(methyl)-benzimidazole
M0286
HMS1747B01
CHEBI:194887
methylbenzimidazole
AKOS000119165
A15695
2-methyl-1h-benzoimidazole
bdbm50404850
BP-12750
2-methyl-1h-1,3-benzodiazole
F0401-0069
FT-0613007
AB00442
SCHEMBL111276
AM808087
AB00981800-01
DTXSID5060641
2-methyl-benzimidazole
2-methylbenzoimidazole
2-methyl benzimidazole
2-methybenzimidazole
1h-2-methylbenzimidazole
1h-2-methylbenzimidazol
DS-1554
TS-01713
Q-101088
CS-W013410
8p7 ,
2-methyl-1~{h}-benzimidazole
mfcd00005598
2-methylbenzimidazole, vetec(tm) reagent grade, 98%
Z55692894
SY015991
4-(trifluoromethyl)pyridine-3-carboxylicacidhydrazide
BCP27368
2-methylbenzo[d]imidazole
EN300-16420
AC7835
Q27295516
2-methyl-1h-1,3-benzimidazole

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"A new series of novel benzimidazole derivatives containing substituted pyrid-2-yl moiety and polyhydroxy sugar conjugated to the N-benzimidazole moiety has been synthesized and evaluated as orally bioavailable anti-inflammatory agents with anti-ulcerogenic activity."( Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity.
Biuomy, AR; El-Nezhawy, AO; Hassan, FS; Ismaiel, AK; Omar, HA, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)IC50 (µMol)1,075.76007.40007.80008.2000AID38394; AID38395
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)Ks440.00001.10001.10001.1000AID184443
Cytochrome P450 1A1Rattus norvegicus (Norway rat)Ks510.00001.70001.70001.7000AID184441
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)Ks510.00001.70001.70001.7000AID184441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID39088Inhibition of Aryl hydrocarbon hydroxylase in phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID288164Inhibition baboon liver mitochondrial MAOB2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues.
AID289355Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 0.32 nmol relative to control2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
AID184443Interaction with cytochrome P450 in Phenobarbitone-induced rat hepatic microsomes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID210974Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation; No reduction observed2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID284279Antiamnesic activity against Entamoeba histolytica2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
AID374579Apparent permeability across bovine cornea assessed as lag time of permeation by UV-visible spectrophotometer2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea.
AID184441Interaction with cytochrome P450 in 3-methylcholanthrene-induced rat hepatic microsomes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID38395Inhibition of Aminopyrine N-demethylase in Phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID38394Inhibitory potency to aminopyrine N-demethylase activity (P450) in hepatic microsomes from phenobarbitone-induced rats.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID24235Partition coefficient (logP)1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID727731Dissociation constant, pKa of the compound at pH 3 to 12 by UV spectroscopy2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Rapid Determination of Ionization Constants (pK a) by UV Spectroscopy Using 96-Well Microtiter Plates.
AID289353Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 16 nmol relative to control2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
AID39089Inhibition of Aryl hydrocarbon hydroxylase in phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID289356Cytotoxicity against Raji cells assessed as cell viability at 32 nmol relative to control2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
AID289352Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 32 nmol relative to control2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
AID26812Partition coefficient (logP)1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID75268The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID374578Apparent permeability across bovine cornea by UV-visible spectrophotometer2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea.
AID67529The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID289354Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells at 3.2 nmol relative to control2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (26.09)18.7374
1990's2 (8.70)18.2507
2000's6 (26.09)29.6817
2010's8 (34.78)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.23 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index39.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]